Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 65% of modeled bridge. Strengths: Occupancy Rate. Risks: Bed Count. Risk-adjusted uplift: $23.8M (vs $36.8M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $14.0M | $14.0M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $13.5M | $385K | $13.8M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $2.1M | $6.4M | $8.5M | $26.8M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $447K | $447K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 21.3% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $3.5M | $7.0M | $10.5M | $14.0M | $14.0M | $14.0M | $14.0M |
| Denial Rate Reduction | $0 | $3.5M | $6.9M | $10.4M | $13.8M | $13.8M | $13.8M | $13.8M |
| A/R Days Reduction | $0 | $2.8M | $5.7M | $8.5M | $8.5M | $8.5M | $8.5M | $8.5M |
| Clean Claim Rate | $0 | $224K | $447K | $447K | $447K | $447K | $447K | $447K |
| Cumulative | $0 | $10.0M | $20.0M | $29.8M | $36.8M | $36.8M | $36.8M | $36.8M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $36.8M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | Loss | Loss | Loss | Loss | Loss |
| 9.0x | Loss | Loss | Loss | Loss | Loss |
| 10.0x | -100% / 0.0x | Loss | Loss | Loss | Loss |
| 11.0x | -100% / 0.0x | -100% / 0.0x | Loss | Loss | Loss |
| 12.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | Loss | Loss |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 0% before the 6.5x covenant trips. RCM uplift reduces leverage from 99.0x to 99.0x, adding 0.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $-59.6M | — | $-59.6M | -8.5% |
| Year 1 | $-61.4M | +$24.5M | $-36.9M | -5.3% |
| Year 2 | $-63.3M | +$36.8M | $-26.5M | -3.8% |
| Year 3 | $-65.2M | +$36.8M | $-28.4M | -4.1% |
| Year 4 | $-67.1M | +$36.8M | $-30.3M | -4.3% |
| Year 5 | $-69.1M | +$36.8M | $-32.3M | -4.6% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $7.0M | $10.5M | $14.0M | $16.8M |
| Denial Rate Reductio | $6.9M | $10.4M | $13.8M | $16.6M |
| A/R Days Reduction | $4.3M | $6.4M | $8.5M | $10.2M |
| Clean Claim Rate | $224K | $336K | $447K | $537K |
| Total | $18.4M | $27.6M | $36.8M | $44.1M |
Peer Context — Where This Hospital Sits
Key metrics vs 55 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | -8.5% | -7.0% | 5.7% | 15.7% | P20 |
| Net-to-Gross | 17.3% | 10.4% | 18.6% | 21.3% | P44 |
| Occupancy | 60.9% | 59.3% | 66.2% | 76.1% | P31 |
| Rev/Bed | $1.2M | $1.0M | $1.2M | $1.7M | P37 |
| Exp/Bed | $1.3M | $898K | $1.1M | $1.6M | P60 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.